Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Overexpression of Calreticulin Impairs Self-Renewal Capacity of Hematopoietic Stem Cells

Stefan Brooks, Sarah Morse, MS, Brianna Craver, MS, Hew Yeng Lai, Thanh Kim Nguyen, PhD, Daniel Kim, Angela G. Fleischman, MD PhD, Prasanthi Tata, Nilamani Jena, PhD, Zhong-Ying Liu, Richard A. Van Etten, MD PhD

Blood (2017) 130 (Supplement 1): 4937.

https://doi.org/10.1182/blood.V130.Suppl_1.4937.4937

Published: 2017

Journal Articles

The MEK/ERK Inhibitor Trametinib Reduces Fibrosis in a Transduction-Transplantation Model of Mutated Calreticulin

Thanh Kim Nguyen, PhD, Prasanthi Tata, Stefan Brooks, BA, Nilamani Jena, PhD, Sarah J Morse, MS, BS, Zhong-ying Liu, Hew Yeng Lai, BS, Sherif Rezk, MD, Richard A. Van Etten, MD PhD, Angela G Fleischman, MD PhD

Blood (2016) 128 (22): 635.

https://doi.org/10.1182/blood.V128.22.635.635

Published: 2016

Journal Articles

Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment

Daniela S. Krause, M.D., Ph.D., Keertik Fulzele, PhD, Andre Catic, MD PhD, Michael Hurley, Sanon Lezeau, Eyal C. Attar, MD, Joy Y. Wu, Herbert Yih-Fuu Lin, MD, PhD, Paola Divieti-Pajevic, MD PhD, Robert Hasserjian, MD, Ernestina Schipani, MD, Richard A. Van Etten, MD PhD, David T. Scadden, MD

Blood (2012) 120 (21): 1245.

https://doi.org/10.1182/blood.V120.21.1245.1245

Published: 2012

Journal Articles

Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Reduces Leukemic Stem Cells in Murine Chronic Myelogenous-Leukemia-Like Disease Via a TGFbeta-Dependent Pathway

Daniela S. Krause, MD, PhD, Keertik Fulzele, PhD, Andre Catic, MD PhD, Michael Hurley, Sanon Lezeau, Robert Hasserjian, MD, Joy Wu, MD PhD, Paola Divieti-Pajevic, MD PhD, Richard A. Van Etten, MD PhD, Ernestina Schipani, MD, David T. Scadden, MD

Blood (2011) 118 (21): 1670.

https://doi.org/10.1182/blood.V118.21.1670.1670

Published: 2011

Journal Articles

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

Jorge E. Cortes, Moshe Talpaz, MD, Hagop M Kantarjian, Hedy Smith, MD, PhD, Dale Bixby, MD, PhD, Usha Rafferty, MS, Mark S. Berger, MD, Scott C. Wise, MS, Tom J. Rutkoski, Ph.D, Bryan Smith, Ph.D, Richard A. Van Etten, MD PhD

Blood (2011) 118 (21): 601.

https://doi.org/10.1182/blood.V118.21.601.601

Published: 2011

Journal Articles

Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,

Furha I. Cossor, MD, Sandy Wong, MD, Kenneth B Miller, MD, Deborah Black, RN, Raymond L. Comenzo, MD, Andreas K. Klein, MD, Alanna Klekar, RN, Valerie Relias, PharmD, Hedy Smith, MD, PhD, Kellie Sprague, MD, Karen M Switkowski, MS, MPH, Richard A. Van Etten, MD PhD, Hans-Georg Klingemann, MD, PhD

Blood (2011) 118 (21): 4153.

https://doi.org/10.1182/blood.V118.21.4153.4153

Published: 2011

Journal Articles

Targeting CXCR4 with Cell-Penetrating Pepducins Enhances Survival in Disseminated Lymphoma

Lidija Covic, Katie M O’Callaghan, PhD, Nga Ngyen, Hsieh Mo-Ying, Andreas K. Klein, MD, Kellie Sprague, MD, Richard A. Van Etten, MD PhD, Athan Kuliopulos, MD, PhD

Blood (2011) 118 (21): 4244.

https://doi.org/10.1182/blood.V118.21.4244.4244

Published: 2011

Journal Articles

Mouse Models of Myeloproliferative Neoplasms and Their Use In Preclinical Drug Testing

Richard A. Van Etten, MD, PhD

Blood (2010) 116 (21): SCI-35.

https://doi.org/10.1182/blood.V116.21.SCI-35.SCI-35

Published: 2010

Journal Articles

Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study

Hans-Georg Klingemann, MD, PhD, Carrie Grodman, RN, Andreas K. Klein, MD, Kellie Sprague, MD, Kenneth B. Miller, MD, Tarun Kewalramani, MD, Raymond L. Comenzo, MD, Neng Yu, MD, Marvin Duque, MD, Richard A. Van Etten, MD, PhD, David McKenna, MD

Blood (2010) 116 (21): 4299.

https://doi.org/10.1182/blood.V116.21.4299.4299

Published: 2010

Journal Articles

Distinct Roles for the NF-κB Pathway In Myeloid and Lymphoid Transformation and Leukemogenesis by BCR-ABL.

Mo-Ying Hsieh, BS, Richard A. Van Etten, MD, PhD

Blood (2010) 116 (21): 1225.

https://doi.org/10.1182/blood.V116.21.1225.1225

Published: 2010

Journal Articles

Transfection of NK Cells with mRNA or Lentivirus Expressing Chimeric Antigen Receptors Results in Highly Efficient Killing of Lymphoid Malignancies and Compares Favorably with Monoclonal Antibody-Directed ADCC.

Laurent Boissel, PhD, Monica Betancur, MSc, Richard A. Van Etten, MD, PhD, Hans-Georg Klingemann, MD, PhD

Blood (2009) 114 (22): 1696.

https://doi.org/10.1182/blood.V114.22.1696.1696

Published: 2009

Journal Articles

Essential Role for Stat5a/b in Myeloproliferative Neoplasms Induced by BCR-ABL1 and Jak2 V617F.

Christoph Walz, MD, Katherine Lazarides, Nihal Patel, Lothar Hennighausen, PhD, Virginia M. Zaleskas, MD, Richard A. Van Etten, MD, PhD

Blood (2009) 114 (22): 312.

https://doi.org/10.1182/blood.V114.22.312.312

Published: 2009

Journal Articles

Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL

M. Golam Mohi, PhD, Wayne W. Chan, BA, Shaoguang Li, MD, PhD, Benjamin Neel, MD, PhD, Richard A. Van Etten, MD, PhD

Blood (2008) 112 (11): 570.

https://doi.org/10.1182/blood.V112.11.570.570

Published: 2008

Journal Articles

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

Richard A. Van Etten, MD, PhD, Wayne W. Chan, BA, Virginia M. Zaleskas, MD, Christoph Walz, MD, Peter Evangelista, BA, Katherine Lazarides, BS, Monica Betancur, MS, Scott Wise, MS, Peter A. Petillo, PhD, Daniel L. Flynn, PhD

Blood (2008) 112 (11): 576.

https://doi.org/10.1182/blood.V112.11.576.576

Published: 2008

Journal Articles

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

Virginia M. Zaleskas, MD, Wayne W. Chan, BS, Peter Evangelista, BS, Katherine Lazarides, BS, Rajesh Chopra, MD, Michael Zinda, PhD, Dennis Huszar, PhD, Richard A. Van Etten, MD PhD

Blood (2007) 110 (11): 557.

https://doi.org/10.1182/blood.V110.11.557.557

Published: 2007

Journal Articles

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

Richard A. Van Etten, MD, PhD, Wayne W. Chan, BS, Virginia M. Zaleskas, MD, PhD, Peter Evangelista, BS, Katherine Lazarides, BS, Cong Peng, PhD, Shaoguang Li, MD, PhD, Scott C. Wise, PhD, Peter Petillo, PhD, Daniel L. Flynn, PhD

Blood (2007) 110 (11): 463.

https://doi.org/10.1182/blood.V110.11.463.463

Published: 2007

Journal Articles

A Chromatin-Associated Histone H3 Dementhylase Promotes the Immortalization of MEFs and the Cycling of HSC-Like Cells in Culture.

Raymond Pfau, BS, Alexandros Tzatsos, MD, PhD, Susan E. Bear, PhD, Christos Polytarchou, PhD, Sotirios Kampranis, PhD, Richard A. Van Etten, MD, PhD, Philip N. Tsichlis, MD

Blood (2007) 110 (11): 96.

https://doi.org/10.1182/blood.V110.11.96.96

Published: 2007

Journal Articles

Distinct Leukemogenic Activity and Imatinib Responsiveness of a BCR-PFGFRα Fusion Tyrosine Kinase.

L. Cristina Gavrilescu, PhD, Nicholas C.P. Cross, PhD, Richard A. Van Etten, MD, PhD

Blood (2006) 108 (11): 3634.

https://doi.org/10.1182/blood.V108.11.3634.3634

Published: 2006

Journal Articles

CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells.

Daniela S. Krause, MD, PhD, Katherine Lazarides, BS, Ulrich H. von Andrian, MD, PhD, Richard A. Van Etten, MD, PhD

Blood (2006) 108 (11): 743.

https://doi.org/10.1182/blood.V108.11.743.743

Published: 2006

Journal Articles

Molecular Pathogenesis of Polycythemia Induced in Mice by JAK2 V617F.

Virginia M. Zaleskas, MD, Daniela S. Krause, MD, PhD, Katherine Lazarides, BS, Nihal Patel, BS, Yiguo Hu, BS, Shaoguang Li, MD, PhD, Richard A. Van Etten, MD, PhD

Blood (2005) 106 (11): 116.

https://doi.org/10.1182/blood.V106.11.116.116

Published: 2005

NARROW

Overexpression of Calreticulin Impairs Self-Renewal Capacity of Hematopoietic Stem Cells

The MEK/ERK Inhibitor Trametinib Reduces Fibrosis in a Transduction-Transplantation Model of Mutated Calreticulin

Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment

Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Reduces Leukemic Stem Cells in Murine Chronic Myelogenous-Leukemia-Like Disease Via a TGFbeta-Dependent Pathway

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Patients ≥ 60 Years of Age with a Novel Reduced Intensity Conditioning Regimen Incorporating Extracorporeal Photopheresis,

Targeting CXCR4 with Cell-Penetrating Pepducins Enhances Survival in Disseminated Lymphoma

Mouse Models of Myeloproliferative Neoplasms and Their Use In Preclinical Drug Testing

Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study

Distinct Roles for the NF-κB Pathway In Myeloid and Lymphoid Transformation and Leukemogenesis by BCR-ABL.

Transfection of NK Cells with mRNA or Lentivirus Expressing Chimeric Antigen Receptors Results in Highly Efficient Killing of Lymphoid Malignancies and Compares Favorably with Monoclonal Antibody-Directed ADCC.

Essential Role for Stat5a/b in Myeloproliferative Neoplasms Induced by BCR-ABL1 and Jak2 V617F.

Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

A Chromatin-Associated Histone H3 Dementhylase Promotes the Immortalization of MEFs and the Cycling of HSC-Like Cells in Culture.

Distinct Leukemogenic Activity and Imatinib Responsiveness of a BCR-PFGFRα Fusion Tyrosine Kinase.

CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells.

Molecular Pathogenesis of Polycythemia Induced in Mice by JAK2 V617F.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only